Race Oncology Limited (ASX: RAC) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Race Oncology Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Race Oncology Limited (ASX: RAC)
Latest News
Share Fallers
Why Computershare, Macquarie, Race Oncology, & Webjet are tumbling lower
Share Market News
Race (ASX:RAC) share price falters despite positive update
Share Market News
Up 1,460% in a year, why the Race Oncology (ASX:RAC) share price is sliding today
Share Market News
Race Oncology (ASX:RAC) share price slides on a new melanoma preclinical study
Share Market News
Race Oncology (ASX: RAC) share price higher on preclinical breast cancer results
Share Market News
Subreddit ASX Bets is gambling these 4 ASX shares will follow in GameStop's footsteps
Share Market News
Up 61% in 2021, why the Race Oncology (ASX:RAC) share price is marching higher again
Share Market News
What sent the Race Oncology (ASX:RAC) share price rocketing 20% today?
Share Market News
ASX small caps could get a boost with the Aussie dollar hitting 28-month highs
Speculative
Why the Race Oncology share price opened 75% higher this morning
Frequently Asked Questions
-
No, Race Oncology does not pay dividends at this time.
-
Sydney-headquartered Race Oncology Ltd listed on the ASX on 13 July 2016.
RAC ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Race Oncology Limited
Race Oncology Ltd (ASX: RAC) is a clinical-stage global biotechnology company focused on cancer care.
Race’s lead asset, bisantrene, is a small-molecule anthracene chemotherapeutic. It has demonstrated anti-cancer and cardio-protection effects in 46 clinical trials and around 70 peer-reviewed publications.
The company is now taking its next-generation bisantrene to new fields of cancer treatment. It is initially focusing on two areas of unmet need: metastatic breast cancer (lead indication) and acute myeloid leukaemia (AML).
As part of its business strategy and clinical program, Race is also investigating the impact bisantrene and new molecules have on the m6A RNA pathway. This follows independent research describing bisantrene as the most potent inhibitor of fat mass and obesity-associated protein (FTO). Dysregulation of RNA (or the over-expression of FTO) has been shown to be a driver of a diverse range of cancers. Race and its partners are now in pre-clinical studies to explore the synergies and impact of bisantrene on FTO regulation.
